Celgene (NASDAQ:CELG) has been assigned a $166.00 price target by Oppenheimer in a research report issued on Friday. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Oppenheimer’s price target suggests a potential upside of 56.12% from the stock’s previous close.
Other research analysts also recently issued reports about the stock. UBS Group downgraded shares of Celgene from a “strong-buy” rating to a “market perform” rating and set a $160.00 price objective on the stock. in a research report on Thursday, October 26th. BMO Capital Markets lowered their target price on shares of Celgene from $163.00 to $148.00 and set an “outperform” rating on the stock in a report on Friday, October 27th. Stifel Nicolaus lowered their target price on shares of Celgene from $149.00 to $130.00 and set a “buy” rating on the stock in a report on Friday. Jefferies Group reaffirmed a “buy” rating and issued a $160.00 target price on shares of Celgene in a report on Friday, September 15th. Finally, BTIG Research reaffirmed a “neutral” rating on shares of Celgene in a report on Tuesday, September 5th. One investment analyst has rated the stock with a sell rating, twelve have given a hold rating, twenty-one have given a buy rating and one has given a strong buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $135.43.
Shares of Celgene (CELG) opened at $106.33 on Friday. Celgene has a one year low of $94.55 and a one year high of $147.17. The company has a debt-to-equity ratio of 1.31, a quick ratio of 3.52 and a current ratio of 3.65. The company has a market cap of $84,935.75, a price-to-earnings ratio of 25.26, a P/E/G ratio of 0.84 and a beta of 1.78.
In other news, insider Terrie Curran sold 1,727 shares of the business’s stock in a transaction that occurred on Monday, September 25th. The shares were sold at an average price of $143.89, for a total value of $248,498.03. Following the completion of the transaction, the insider now owns 3,925 shares of the company’s stock, valued at $564,768.25. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 0.95% of the company’s stock.
Large investors have recently bought and sold shares of the company. Neuberger Berman Group LLC grew its position in shares of Celgene by 4.0% during the first quarter. Neuberger Berman Group LLC now owns 1,844,837 shares of the biopharmaceutical company’s stock worth $229,553,000 after acquiring an additional 71,729 shares during the last quarter. Grisanti Capital Management LLC bought a new position in shares of Celgene during the second quarter worth about $3,616,000. Lincoln Capital Corp grew its position in shares of Celgene by 0.6% during the second quarter. Lincoln Capital Corp now owns 30,580 shares of the biopharmaceutical company’s stock worth $3,971,000 after acquiring an additional 185 shares during the last quarter. RiverPoint Capital Management LLC grew its position in shares of Celgene by 3.1% during the second quarter. RiverPoint Capital Management LLC now owns 121,654 shares of the biopharmaceutical company’s stock worth $15,799,000 after acquiring an additional 3,680 shares during the last quarter. Finally, Russell Investments Group Ltd. grew its position in shares of Celgene by 9.2% during the second quarter. Russell Investments Group Ltd. now owns 641,697 shares of the biopharmaceutical company’s stock worth $83,344,000 after acquiring an additional 54,210 shares during the last quarter. 79.84% of the stock is owned by institutional investors and hedge funds.
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.